2025年1月14日 · Bavdegalutamide (ARV-110) is a PROteolysis TArgeting Chimera (PROTAC) protein degrader that recruits the cereblon-containing E3 ubiquitin ligase to direct the …

ARV-110 Demonstrates Efficacy and Plasma PSA Reduction in an Enzalutamide-Insensitive PDX Model ARV-110 is showing early clinical benefit in highly refractory patients

2022年2月16日 · Conclusions: ARV-110, a novel AR protein degrader, demonstrates clinical activity in a post-NHA, heavily pretreated mCRPC pt population, with greatest PSA 50 activity …

About Bavdegalutamide (ARV-110) Bavdegalutamide is an investigational orally bioavailable PROTAC® protein degrader designed to selectively target and degrade the androgen receptor …

Bavdegalutamide, also called ARV-110, is a drug that is being evaluated as a treatment for metastatic prostate cancer. It is a PROteolysis TArgeting Chimera (PROTAC) androgen …

2019年2月26日 · ARV-110 treatment leads to highly selective AR degradation, as demonstrated by proteomic studies. In VCaP cells, PROTAC-mediated AR degradation suppresses the …

ARV-110, a novel proteolysis-targeting chimera (PROTAC), has been reported to show satisfactory safety and tolerability for prostate cancer therapy in phase I clinical trials. …

2025年1月1日 · Proteomic screening analysis revealed that treatment with ARV-110 at a concentration of 10 nM selectively degraded up to 85% of AR in VCaP cells. Compared with …

2020年5月25日 · ARV-110 is an orally bioavailable PROTAC that specifically degrades AR ≥ 95% and achieves anti-tumor activity in ENZ-naïve and -resistant prostate cancer xenograft models.

Bavdegalutamide (ARV-110) is an orally active, specific androgen receptor (AR) PROTAC degrader. Bavdegalutamide promotes ubiquitination and degradation of AR. Bavdegalutamide …